

If you cannot see this email, please [click here](#)



Newsletter Corporate - May 2017

Dear Members,

Just like every year, the time has come for BioWin to review its figures from the past few months and share the results with you!

Furthermore, the cluster's activities are doing well, especially in the Europe Cell.

#### Summary:

- The results from 2016 show that the cluster is continuing to grow
- A record year in terms of investment in R&D
- The new director of the Europe Cell has brought a new impetus to the unit
- International events not to be missed!

Happy reading!



### Cluster's results 2016: A continuous and positive evolution

- Employment has continued to grow since 2005
  - Total: 16,960 jobs, i.e. an average annual development of **+7.7%**(2005-2016)
  - SME: 4,049 jobs, i.e. an average annual development of **+17.9%**(2005-2016)
- Number of new members in 2016: 21
  - 7 large companies
  - 157 innovative SME

[Read the complete press release](#)

### Significant increase in private equity in the SME

Over the past 11 years (2005-2016), the SME members of BioWin accumulated a market capitalisation of more than € 1 billion.

[Read More >>](#)



### 2016: a record year in R&D with 8 labelled projects for a total of EUR 24.6 million

8 projects that fall within the scope of the cluster's priority themes, such as digital technologies, medical implants, drug discovery and radiation therapy, were labelled



by BioWin in 2016. This portfolio of projects represents a total budget of **EUR 24.6 million**, with EUR 7 million in private investment.

[Read the press release here](#) (only available in French)

## The Europe Cell at the heart of the action

The Europe Cell started the year well with its activities that focus on helping its members to set up European projects.

- **Horizon 2020**: BioWin helped a Walloon SME to submit a project proposal in mid-April for the following call: **Societal Challenge 1 (SC1)** in **clinical research** in the field of **regenerative medicine**.
- Two **inter-cluster projects** in the field of **nuclear medicine** and **bioproduction** between different European regions.
- An **interreg research project in 3D printing** between the north of France, Flanders and Wallonia.
- **Creating closer ties** between the cluster and **other key European structures** for certain sectors (cellular therapy, radiation therapy, bioproduction, etc.)

[Read More >>](#)

## International events

Where were our members during the past few weeks?

**BioEurope Spring - Barcelona, from 20 to 22 March**

As in previous years, BioWin took part in **BioEurope Spring**, a quality event for our stakeholders! **18 Walloon companies** in total were present. Moreover, thanks to the cluster, **iTeos Therapeutics** and **OncoDNA** spoke at the conference.

[Read More >>](#)

## International events not to be missed!

- **A3P - 31 May, 1 June in Lyon**  
Learn more about key trends, methodologies and ideas on manufacturing, process development, quality management and the conformity of bioproducts.
- **RegMed Europe - 7 July in Paris**  
First European networking event in regenerative medicine
- **NLSDAYS - 12 - 14 September in Malmö**  
The Nordic Life Science Days will provide you with an overview of the **most recent trends** in life sciences and will give you the



opportunity to meet the main decision-makers in the sectors of biotechnology, pharmaceuticals and medicine, as well as representatives from finance, research and regulatory bodies, as well as policy-makers.

[Click here to find out more about our events](#)

## New member

Welcome to...

**DROIA** is a risk capital investor with a particular focus on the development of cancer therapies.



### Suivez-nous !



LinkedIn



Twitter (BioWin\_asbl)

### Nos partenaires



Wallonie



Wallonia.be

EUROPE INVESTMENT



PLAN MARSHALL 4.0



Maison de l'Industrie Technologique  
Rue Auguste Piccard, 20  
6041 Gosselies



Tél : +32 (0)71/91.92.85



Email : [contact@biowin.org](mailto:contact@biowin.org)

Si vous ne souhaitez plus recevoir d'e-mails de notre part, [suivez ce lien](#)